Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
195 shown of 8,422 total abstracts
  1. Abstract 46102026-04-03 · 20:45 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-398
    G. Curigliano, C. Robert, S. Modi, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  2. Abstract 11982026-04-04 · 20:00 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    C. Robert, J. Brahmer, S. Antonia · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  3. Abstract 48562026-04-01 · 15:15 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in HCC
    S. Tolaney, L. Paz-Ares, C. Saura, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  4. Abstract 47512026-04-02 · 14:15 CT · E450
    Long-term follow-up of Padcev maintenance for urothelial carcinoma: EV-962
    A. Spira, H. Borghaei, H. Rugo, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  5. Abstract 13242026-04-03 · 15:45 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    M. Reck, S. Antonia · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  6. Abstract 12512026-04-03 · 21:00 CT · Arie Crown Theater
    Keytruda plus chemotherapy in previously untreated TNBC: updated analysis from KEYNOTE-11
    S. Modi, S. Peters, S. Tolaney, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  7. Abstract 15882026-04-04 · 13:30 CT · Hall B1
    MONALEESA-141: Kisqali (ribociclib) 1L in HR+ breast cancer
    R. Herbst, J. Brahmer, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  8. Abstract 14412026-04-04 · 19:15 CT · Hall B1
    KEYNOTE-47: Keytruda (pembrolizumab) neoadjuvant in TNBC
    R. Herbst, J. Brahmer, E. Winer · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  9. Abstract 42802026-04-04 · 15:00 CT · S406
    Long-term follow-up of Padcev 2L for urothelial carcinoma: EV-356
    L. Paz-Ares, F. Andre, C. Saura · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  10. Abstract 16112026-04-01 · 16:00 CT · E450
    MONARCH-91: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    S. Antonia, C. Saura · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  11. Abstract 48442026-04-02 · 16:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-707
    T. Mok, H. Borghaei, M. Reck · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  12. Abstract 44942026-04-02 · 18:30 CT · S100A
    DESTINY-Breast-269: Enhertu (trastuzumab deruxtecan) neoadjuvant in gastric
    L. Paz-Ares, A. Spira, M. Reck, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  13. Abstract 10162026-04-02 · 15:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with TNBC
    R. Herbst, S. Peters, S. Tolaney · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  14. Abstract 44302026-04-01 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in gastric (the DESTINY-Breast-261 study)
    S. Modi, T. Mok, H. Borghaei, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  15. Abstract 58552026-04-03 · 21:45 CT · S406
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-24
    S. Antonia, H. Borghaei, C. Robert, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  16. Abstract 10292026-04-02 · 20:15 CT · S406
    MONALEESA-375: Kisqali (ribociclib) maintenance in HR+ breast cancer
    S. Antonia, A. Spira, N. Rizvi, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  17. Abstract 96052026-04-02 · 21:30 CT · E450
    Long-term follow-up of Imfinzi 2L for SCLC: PACIFIC-453
    E. Winer, F. Andre, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  18. Abstract 47642026-04-01 · 21:00 CT · S406
    EV-381: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    E. Winer, H. Rugo, R. Herbst, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  19. Abstract 99232026-04-01 · 13:30 CT · S406
    FLAURA-490: Tagrisso (osimertinib) 3L+ in NSCLC
    S. Tolaney, N. Rizvi · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  20. Abstract 48852026-04-03 · 15:45 CT · Arie Crown Theater
    ASCENT-772: Trodelvy (sacituzumab govitecan) 3L+ in urothelial carcinoma
    E. Winer, J. Cortes, F. Andre · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  21. Abstract 13862026-04-03 · 20:15 CT · E450
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-241
    M.C. Garassino, J. Cortes, H. Borghaei, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  22. Abstract 53632026-04-02 · 19:30 CT · S100A
    OlympiA-619: Lynparza (olaparib) 3L+ in prostate
    P. Schmid, A. Spira, J. Cortes, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  23. Abstract 49332026-04-04 · 14:00 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in urothelial carcinoma
    E. Winer, T. Mok · Cleveland Clinic
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  24. Abstract 17622026-04-05 · 19:15 CT · Hall B1
    Long-term follow-up of Ibrance adjuvant for HR+ breast cancer: PALOMA-594
    S. Peters, L. Paz-Ares · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  25. Abstract 42982026-04-01 · 13:30 CT · S100A
    Quality of life outcomes with Trodelvy in patients with urothelial carcinoma
    J. Cortes, G. Curigliano, C. Robert, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  26. Abstract 19722026-04-05 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-892 study)
    S. Peters, L. Paz-Ares · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  27. Abstract 96742026-04-05 · 18:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-400
    L. Paz-Ares, T. Mok, M. Krop · University of Chicago
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 91662026-04-01 · 14:30 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-746 study)
    S. Antonia, T. Mok · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 40162026-04-05 · 19:00 CT · Hall B1
    Real-world effectiveness of Enhertu vs standard of care in gastric
    C. Saura, J. Brahmer · Massachusetts General Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  30. Abstract 14252026-04-02 · 15:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-808 study)
    M. Reck, P. Schmid, J. Cortes · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  31. Abstract 96922026-04-05 · 21:30 CT · E450
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    J. Cortes, F. Andre, H. Borghaei, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 15842026-04-03 · 19:45 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-612 study)
    L. Paz-Ares, M. Reck · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  33. Abstract 91622026-04-02 · 19:45 CT · S406
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-699 study)
    S. Peters, N. Rizvi, M. Krop, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  34. Abstract 90812026-04-01 · 21:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with NSCLC
    M.C. Garassino, A. Spira, R. Herbst · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  35. Abstract 96182026-04-01 · 16:00 CT · S406
    Quality of life outcomes with Enhertu in patients with NSCLC
    A. Spira, N. Rizvi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 91402026-04-05 · 21:00 CT · E450
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-265
    P. Schmid, H. Borghaei, H. Rugo, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  37. Abstract 15152026-04-02 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-759 study)
    E. Winer, M.C. Garassino · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  38. Abstract 19012026-04-05 · 18:45 CT · S406
    MONARCH-816: Verzenio (abemaciclib) adjuvant in HR+ breast cancer
    S. Tolaney, C. Saura · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  39. Abstract 93132026-04-02 · 18:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-728 study)
    C. Robert, H. Borghaei, L. Paz-Ares, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 99282026-04-03 · 19:30 CT · S406
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    S. Peters, H. Rugo, J. Cortes, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  41. Abstract 41592026-04-01 · 19:30 CT · E450
    EV-605: Padcev (enfortumab vedotin) 1L in urothelial carcinoma
    T. Mok, H. Borghaei, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  42. Abstract 66262026-04-05 · 21:30 CT · Hall B1
    Long-term follow-up of Opdivo adjuvant for RCC: CheckMate-720
    H. Borghaei, A. Spira, P. Schmid, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  43. Abstract 43882026-04-03 · 15:00 CT · S406
    Real-world effectiveness of Imfinzi vs standard of care in biliary tract
    J. Cortes, M.C. Garassino, T. Mok, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  44. Abstract 43002026-04-03 · 14:45 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-722
    F. Andre, H. Rugo, S. Peters · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  45. Abstract 18862026-04-01 · 21:15 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-407
    C. Robert, T. Mok · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  46. Abstract 91492026-04-01 · 13:00 CT · S406
    Long-term follow-up of Keytruda 3L+ for NSCLC: KEYNOTE-619
    J. Brahmer, M.C. Garassino, A. Spira, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 14322026-04-05 · 15:30 CT · Arie Crown Theater
    MONARCH-874: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    C. Robert, H. Borghaei, M. Krop · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  48. Abstract 49602026-04-05 · 16:15 CT · S100A
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-917
    E. Winer, H. Rugo, A. Spira · National Cancer Center Japan
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  49. Abstract 46622026-04-01 · 20:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in HCC (the IMpower-976 study)
    E. Winer, L. Paz-Ares, T. Mok · Institut Gustave Roussy
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  50. Abstract 41362026-04-05 · 19:30 CT · E450
    Long-term follow-up of Trodelvy neoadjuvant for urothelial carcinoma: ASCENT-806
    J. Cortes, M.C. Garassino, P. Schmid · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  51. Abstract 11392026-04-01 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in HR+ breast cancer (the DESTINY-Breast-248 study)
    C. Robert, H. Borghaei · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  52. Abstract 95212026-04-01 · 14:30 CT · Hall B1
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    C. Robert, P. Schmid, E. Winer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  53. Abstract 16292026-04-04 · 15:15 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-928 study)
    M. Krop, N. Rizvi, S. Antonia, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  54. Abstract 64702026-04-05 · 14:00 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-177
    M. Reck, F. Andre, H. Borghaei, et al. · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  55. Abstract 90642026-04-05 · 14:30 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    M. Krop, R. Herbst, S. Tolaney, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  56. Abstract 67302026-04-02 · 16:30 CT · E450
    Long-term follow-up of Opdivo maintenance for RCC: CheckMate-576
    M. Reck, P. Schmid · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  57. Abstract 13612026-04-01 · 18:30 CT · S100A
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-256 study)
    M. Krop, C. Saura, S. Modi, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  58. Abstract 103042026-04-05 · 15:30 CT · S100A
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-143 study)
    M. Krop, T. Mok, M.C. Garassino · Cleveland Clinic
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  59. Abstract 18512026-04-05 · 15:30 CT · S406
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-18
    C. Saura, S. Antonia, H. Borghaei · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  60. Abstract 47272026-04-05 · 18:45 CT · S100A
    Real-world effectiveness of Padcev vs standard of care in urothelial carcinoma
    L. Paz-Ares, F. Andre, S. Modi, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  61. Abstract 40322026-04-03 · 20:00 CT · S100A
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-271
    S. Peters, L. Paz-Ares, J. Cortes, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  62. Abstract 40712026-04-05 · 20:00 CT · S406
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-300 study)
    S. Peters, R. Herbst, H. Borghaei · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  63. Abstract 43482026-04-04 · 21:45 CT · Hall B1
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-378
    M. Krop, C. Robert, H. Rugo · National Cancer Center Japan
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  64. Abstract 10322026-04-03 · 20:15 CT · S100A
    Long-term follow-up of Verzenio neoadjuvant for HR+ breast cancer: MONARCH-57
    P. Schmid, N. Rizvi, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  65. Abstract 18532026-04-03 · 18:30 CT · E450
    MONARCH-724: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    A. Spira, H. Rugo, J. Brahmer · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  66. Abstract 96502026-04-05 · 13:45 CT · Arie Crown Theater
    Real-world effectiveness of Keytruda vs standard of care in metastatic melanoma
    S. Peters, R. Herbst · Mayo Clinic
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  67. Abstract 15372026-04-02 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Trodelvy in patients with TNBC
    P. Schmid, T. Mok, M.C. Garassino, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  68. Abstract 99882026-04-01 · 15:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-868
    S. Modi, H. Borghaei · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  69. Abstract 16512026-04-02 · 21:00 CT · E450
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-203
    S. Tolaney, S. Antonia, F. Andre, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  70. Abstract 14632026-04-03 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-791 study)
    L. Paz-Ares, C. Saura, S. Tolaney · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  71. Abstract 98132026-04-02 · 19:30 CT · S406
    Long-term follow-up of Imfinzi adjuvant for SCLC: PACIFIC-106
    P. Schmid, E. Winer, F. Andre, et al. · Mayo Clinic
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  72. Abstract 13812026-04-05 · 21:15 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    M. Reck, M. Krop · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  73. Abstract 44552026-04-05 · 18:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-635
    M. Reck, E. Winer, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  74. Abstract 49612026-04-04 · 18:15 CT · E450
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-686
    S. Peters, H. Rugo, L. Paz-Ares · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  75. Abstract 42062026-04-03 · 15:15 CT · E450
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-268
    L. Paz-Ares, H. Borghaei, T. Mok · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  76. Abstract 60392026-04-01 · 13:15 CT · S406
    Quality of life outcomes with Lynparza in patients with ovarian
    J. Cortes, A. Spira, S. Tolaney, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  77. Abstract 47722026-04-04 · 19:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-199 study)
    C. Robert, E. Winer · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  78. Abstract 65192026-04-02 · 20:45 CT · S406
    Long-term follow-up of Opdivo 2L for RCC: CheckMate-739
    S. Peters, H. Borghaei, N. Rizvi, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  79. Abstract 40692026-04-02 · 18:00 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with gastric
    M.C. Garassino, H. Rugo, S. Peters, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  80. Abstract 91022026-04-03 · 16:30 CT · E450
    CheckMate-676: Opdivo (nivolumab) adjuvant in NSCLC
    C. Saura, S. Peters, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 98072026-04-03 · 19:00 CT · E450
    IMpower-222: Tecentriq (atezolizumab) neoadjuvant in NSCLC
    C. Saura, M.C. Garassino, S. Modi · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  82. Abstract 49792026-04-03 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-195 study)
    M.C. Garassino, S. Tolaney, T. Mok, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  83. Abstract 91722026-04-03 · 21:15 CT · Hall B1
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-368
    S. Tolaney, A. Spira, H. Borghaei, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  84. Abstract 10052026-04-04 · 18:00 CT · S100A
    Long-term follow-up of Lynparza neoadjuvant for HR+ breast cancer: OlympiA-260
    R. Herbst, H. Rugo · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  85. Abstract 40372026-04-02 · 19:45 CT · S406
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-709 study)
    M. Krop, C. Robert, J. Brahmer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  86. Abstract 16952026-04-03 · 20:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-472 study)
    N. Rizvi, S. Modi, P. Schmid, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  87. Abstract 19372026-04-01 · 16:45 CT · Arie Crown Theater
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    R. Herbst, E. Winer · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  88. Abstract 16872026-04-01 · 13:15 CT · E450
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    A. Spira, M. Krop, S. Antonia · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  89. Abstract 49422026-04-05 · 21:30 CT · S406
    EV-189: Padcev (enfortumab vedotin) maintenance in urothelial carcinoma
    C. Saura, S. Peters · University of Chicago
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  90. Abstract 43212026-04-01 · 14:15 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-280
    S. Peters, T. Mok, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  91. Abstract 97462026-04-01 · 16:45 CT · Arie Crown Theater
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    P. Schmid, S. Peters, J. Brahmer, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  92. Abstract 42472026-04-01 · 18:00 CT · Arie Crown Theater
    Padcev plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from EV-635
    C. Saura, P. Schmid, L. Paz-Ares, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  93. Abstract 14072026-04-05 · 13:00 CT · S100A
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-123
    S. Modi, N. Rizvi, J. Brahmer · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  94. Abstract 44852026-04-01 · 14:30 CT · Arie Crown Theater
    Long-term follow-up of Imfinzi 3L+ for biliary tract: PACIFIC-999
    T. Mok, G. Curigliano, C. Saura · Royal Marsden Hospital
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  95. Abstract 10672026-04-01 · 14:45 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    T. Mok, J. Brahmer, R. Herbst, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  96. Abstract 12882026-04-05 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Tecentriq neoadjuvant for TNBC: IMpower-123
    M. Krop, T. Mok · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  97. Abstract 99722026-04-01 · 20:45 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    H. Borghaei, P. Schmid · Stanford Cancer Institute
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  98. Abstract 18072026-04-01 · 20:15 CT · Hall B1
    Long-term follow-up of Ibrance neoadjuvant for HR+ breast cancer: PALOMA-411
    S. Modi, G. Curigliano, T. Mok, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  99. Abstract 14662026-04-05 · 20:15 CT · S100A
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-929
    T. Mok, R. Herbst, L. Paz-Ares, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  100. Abstract 41712026-04-05 · 15:15 CT · S406
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-929
    H. Rugo, A. Spira, S. Peters · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  101. Abstract 95582026-04-05 · 13:00 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-808
    F. Andre, M. Reck · Karolinska Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  102. Abstract 44852026-04-05 · 18:45 CT · E450
    Long-term follow-up of Tecentriq 2L for HCC: IMpower-746
    G. Curigliano, M.C. Garassino, H. Rugo, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  103. Abstract 102832026-04-05 · 18:15 CT · Arie Crown Theater
    CheckMate-988: Opdivo (nivolumab) neoadjuvant in metastatic melanoma
    H. Borghaei, C. Robert, A. Spira, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  104. Abstract 43332026-04-03 · 19:00 CT · S100A
    Long-term follow-up of Trodelvy 1L for urothelial carcinoma: ASCENT-708
    M.C. Garassino, S. Peters, M. Krop · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  105. Abstract 13312026-04-02 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-993
    S. Modi, S. Tolaney, R. Herbst · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  106. Abstract 49822026-04-04 · 20:00 CT · S100A
    IMpower-938: Tecentriq (atezolizumab) neoadjuvant in HCC
    H. Borghaei, L. Paz-Ares, E. Winer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  107. Abstract 98342026-04-02 · 15:15 CT · S406
    FLAURA-585: Tagrisso (osimertinib) maintenance in NSCLC
    F. Andre, M. Krop, P. Schmid · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  108. Abstract 49632026-04-02 · 20:00 CT · Arie Crown Theater
    ASCENT-754: Trodelvy (sacituzumab govitecan) 2L in urothelial carcinoma
    C. Robert, C. Saura, P. Schmid, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  109. Abstract 64512026-04-05 · 14:15 CT · S100A
    Real-world effectiveness of Opdivo vs standard of care in RCC
    M. Reck, S. Tolaney, J. Brahmer · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  110. Abstract 17622026-04-03 · 16:00 CT · S100A
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    S. Antonia, T. Mok, G. Curigliano, et al. · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  111. Abstract 49302026-04-02 · 16:45 CT · E450
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-437
    H. Borghaei, M.C. Garassino, J. Brahmer · Chinese University of Hong Kong
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  112. Abstract 19382026-04-02 · 13:45 CT · Hall B1
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-858
    E. Winer, S. Modi, P. Schmid · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  113. Abstract 48322026-04-04 · 20:15 CT · S100A
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-131
    P. Schmid, C. Saura · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  114. Abstract 14542026-04-04 · 16:30 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    E. Winer, N. Rizvi, R. Herbst · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  115. Abstract 11782026-04-02 · 16:00 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-994
    L. Paz-Ares, S. Antonia · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  116. Abstract 96662026-04-04 · 15:00 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    N. Rizvi, G. Curigliano, P. Schmid, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  117. Abstract 40292026-04-04 · 16:00 CT · E450
    Quality of life outcomes with Opdivo in patients with HCC
    E. Winer, M. Reck, M.C. Garassino · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  118. Abstract 42662026-04-04 · 14:30 CT · E450
    EV-903: Padcev (enfortumab vedotin) 3L+ in urothelial carcinoma
    P. Schmid, S. Tolaney, S. Antonia, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  119. Abstract 95552026-04-04 · 21:30 CT · Hall B1
    FLAURA-768: Tagrisso (osimertinib) neoadjuvant in NSCLC
    T. Mok, E. Winer, S. Tolaney, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  120. Abstract 67332026-04-01 · 20:00 CT · S406
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-768
    J. Cortes, R. Herbst, M.C. Garassino, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  121. Abstract 57402026-04-02 · 19:00 CT · E450
    Real-world effectiveness of Lynparza vs standard of care in ovarian
    L. Paz-Ares, J. Brahmer, H. Borghaei, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  122. Abstract 98542026-04-03 · 18:15 CT · Arie Crown Theater
    FLAURA-501: Tagrisso (osimertinib) 2L in NSCLC
    S. Antonia, S. Tolaney, E. Winer, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  123. Abstract 45642026-04-05 · 19:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Imfinzi in biliary tract (the PACIFIC-836 study)
    S. Peters, C. Robert · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  124. Abstract 91222026-04-01 · 16:30 CT · S406
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-430 study)
    J. Cortes, M.C. Garassino, J. Brahmer, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  125. Abstract 40842026-04-05 · 13:15 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated HCC: updated analysis from IMpower-327
    A. Spira, E. Winer, S. Antonia · Institut Gustave Roussy
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  126. Abstract 18572026-04-01 · 13:30 CT · E450
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-919
    F. Andre, S. Modi, R. Herbst · Institut Gustave Roussy
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  127. Abstract 13022026-04-01 · 18:15 CT · E450
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-469 study)
    R. Herbst, L. Paz-Ares, H. Borghaei, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  128. Abstract 63562026-04-03 · 14:30 CT · E450
    Keytruda plus chemotherapy in previously untreated RCC: updated analysis from KEYNOTE-246
    S. Peters, M.C. Garassino, S. Modi, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  129. Abstract 18342026-04-01 · 21:00 CT · S100A
    Long-term follow-up of Ibrance 3L+ for HR+ breast cancer: PALOMA-564
    P. Schmid, F. Andre, H. Rugo, et al. · Chinese University of Hong Kong
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  130. Abstract 43642026-04-04 · 18:30 CT · E450
    Biomarker subgroup analysis of Trodelvy in urothelial carcinoma (the ASCENT-761 study)
    E. Winer, H. Borghaei · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  131. Abstract 96032026-04-01 · 16:30 CT · S406
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    N. Rizvi, P. Schmid, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  132. Abstract 19352026-04-02 · 20:30 CT · Arie Crown Theater
    Quality of life outcomes with Lynparza in patients with HR+ breast cancer
    R. Herbst, P. Schmid, J. Brahmer, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  133. Abstract 18032026-04-02 · 19:30 CT · E450
    Biomarker subgroup analysis of Keytruda in TNBC (the KEYNOTE-971 study)
    N. Rizvi, G. Curigliano, E. Winer, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  134. Abstract 91672026-04-05 · 21:00 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    M. Reck, N. Rizvi, S. Antonia · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  135. Abstract 10342026-04-03 · 13:45 CT · S406
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    C. Saura, S. Tolaney · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  136. Abstract 13212026-04-02 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-21
    F. Andre, H. Borghaei, P. Schmid, et al. · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  137. Abstract 13112026-04-05 · 15:45 CT · Hall B1
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-315
    M. Krop, H. Borghaei, F. Andre · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  138. Abstract 95812026-04-05 · 19:45 CT · S406
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-85
    S. Antonia, L. Paz-Ares, T. Mok · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  139. Abstract 12932026-04-02 · 14:30 CT · E450
    IMpower-641: Tecentriq (atezolizumab) 3L+ in TNBC
    J. Cortes, G. Curigliano · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  140. Abstract 94022026-04-05 · 20:15 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    J. Brahmer, M.C. Garassino, A. Spira, et al. · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  141. Abstract 57262026-04-02 · 18:30 CT · S100A
    Quality of life outcomes with Lynparza in patients with prostate
    S. Peters, C. Robert, A. Spira, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Prostate📄🖼️🎬
  142. Abstract 44772026-04-05 · 13:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-140 study)
    C. Saura, M.C. Garassino, N. Rizvi · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  143. Abstract 40102026-04-04 · 13:45 CT · S406
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-359
    S. Antonia, S. Modi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  144. Abstract 98122026-04-03 · 18:00 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-691
    S. Peters, R. Herbst, A. Spira · Stanford Cancer Institute
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  145. Abstract 16972026-04-05 · 18:15 CT · S100A
    MONARCH-395: Verzenio (abemaciclib) 1L in HR+ breast cancer
    M. Reck, C. Saura · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  146. Abstract 98762026-04-02 · 13:45 CT · E450
    Biomarker subgroup analysis of Keytruda in NSCLC (the KEYNOTE-250 study)
    J. Cortes, H. Borghaei · National Cancer Center Japan
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  147. Abstract 10082026-04-04 · 20:45 CT · S406
    OlympiA-875: Lynparza (olaparib) adjuvant in HR+ breast cancer
    H. Borghaei, M. Krop · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  148. Abstract 19212026-04-02 · 18:45 CT · Arie Crown Theater
    MONARCH-664: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    M. Reck, S. Tolaney · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  149. Abstract 102062026-04-03 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-91 study)
    C. Saura, F. Andre · Massachusetts General Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  150. Abstract 19932026-04-02 · 16:45 CT · Hall B1
    MONALEESA-231: Kisqali (ribociclib) 2L in HR+ breast cancer
    M. Krop, M. Reck, P. Schmid · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  151. Abstract 95382026-04-01 · 21:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-476 study)
    M. Krop, T. Mok · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  152. Abstract 10882026-04-03 · 21:30 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-252 study)
    T. Mok, S. Antonia, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  153. Abstract 92182026-04-04 · 14:45 CT · S406
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-830
    H. Borghaei, J. Cortes, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  154. Abstract 15802026-04-04 · 19:00 CT · Arie Crown Theater
    DESTINY-Breast-495: Enhertu (trastuzumab deruxtecan) adjuvant in HR+ breast cancer
    M.C. Garassino, C. Saura · Dana-Farber Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  155. Abstract 19772026-04-03 · 14:15 CT · S406
    KEYNOTE-561: Keytruda (pembrolizumab) maintenance in TNBC
    M.C. Garassino, S. Peters, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  156. Abstract 40272026-04-02 · 15:30 CT · E450
    Long-term follow-up of Trodelvy 3L+ for urothelial carcinoma: ASCENT-356
    N. Rizvi, A. Spira, C. Saura · Institut Gustave Roussy
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  157. Abstract 19492026-04-01 · 13:30 CT · S100A
    IMpower-868: Tecentriq (atezolizumab) maintenance in TNBC
    C. Saura, S. Antonia, H. Rugo, et al. · National Cancer Center Japan
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  158. Abstract 13232026-04-02 · 19:45 CT · S100A
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-397
    P. Schmid, S. Tolaney · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  159. Abstract 44172026-04-05 · 20:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 1L for HCC: CheckMate-16
    S. Antonia, S. Peters, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  160. Abstract 93302026-04-04 · 14:30 CT · S100A
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-474
    H. Borghaei, R. Herbst, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  161. Abstract 18262026-04-01 · 15:00 CT · E450
    MONALEESA-935: Kisqali (ribociclib) 1L in HR+ breast cancer
    E. Winer, J. Cortes, M. Reck · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  162. Abstract 12762026-04-04 · 14:15 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    M. Reck, M.C. Garassino · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  163. Abstract 93422026-04-02 · 18:15 CT · S406
    CheckMate-448: Opdivo (nivolumab) 3L+ in NSCLC
    J. Brahmer, C. Robert, G. Curigliano · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  164. Abstract 96802026-04-02 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-238 study)
    H. Borghaei, J. Cortes, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  165. Abstract 14612026-04-02 · 16:00 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-409 study)
    H. Rugo, J. Brahmer, M. Krop, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  166. Abstract 45272026-04-01 · 18:00 CT · Hall B1
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-647 study)
    A. Spira, C. Robert, M. Krop · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  167. Abstract 18802026-04-04 · 14:45 CT · S406
    MONARCH-523: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    C. Saura, M. Reck, H. Borghaei, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  168. Abstract 17762026-04-04 · 21:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-197 study)
    N. Rizvi, F. Andre, S. Peters · University of Chicago
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  169. Abstract 12272026-04-02 · 19:45 CT · Hall B1
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    M.C. Garassino, S. Tolaney, L. Paz-Ares, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  170. Abstract 11632026-04-02 · 14:15 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-691
    S. Peters, C. Robert, J. Brahmer, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  171. Abstract 102712026-04-03 · 13:00 CT · Arie Crown Theater
    KEYNOTE-378: Keytruda (pembrolizumab) maintenance in metastatic melanoma
    J. Cortes, C. Saura · Massachusetts General Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  172. Abstract 58002026-04-02 · 13:15 CT · S100A
    Lynparza plus chemotherapy in previously untreated ovarian: updated analysis from OlympiA-473
    H. Rugo, J. Cortes · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGynecologic Cancer📄🖼️🎬
  173. Abstract 15082026-04-05 · 21:15 CT · E450
    Verzenio plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONARCH-763
    M.C. Garassino, E. Winer, P. Schmid · Cleveland Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  174. Abstract 45152026-04-05 · 14:00 CT · Hall B1
    Long-term follow-up of Padcev neoadjuvant for urothelial carcinoma: EV-875
    H. Rugo, J. Brahmer, S. Antonia, et al. · Karolinska Institute
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  175. Abstract 44342026-04-01 · 18:15 CT · E450
    Quality of life outcomes with Padcev in patients with urothelial carcinoma
    J. Brahmer, H. Borghaei, S. Peters, et al. · Royal Marsden Hospital
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  176. Abstract 49872026-04-02 · 18:15 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated gastric: updated analysis from DESTINY-Breast-880
    E. Winer, G. Curigliano · MD Anderson Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  177. Abstract 40582026-04-04 · 14:00 CT · E450
    Biomarker subgroup analysis of Padcev in urothelial carcinoma (the EV-161 study)
    A. Spira, C. Robert · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  178. Abstract 18072026-04-04 · 18:30 CT · S100A
    MONALEESA-111: Kisqali (ribociclib) maintenance in HR+ breast cancer
    H. Borghaei, E. Winer, H. Rugo · Karolinska Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  179. Abstract 93522026-04-01 · 13:30 CT · S406
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-701 study)
    A. Spira, F. Andre, P. Schmid, et al. · Cleveland Clinic
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  180. Abstract 19432026-04-05 · 16:15 CT · S100A
    OlympiA-692: Lynparza (olaparib) adjuvant in HR+ breast cancer
    T. Mok, S. Tolaney · Mayo Clinic
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  181. Abstract 101832026-04-05 · 19:45 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    A. Spira, S. Modi, C. Saura, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
  182. Abstract 44332026-04-05 · 21:00 CT · S100A
    DESTINY-Breast-501: Enhertu (trastuzumab deruxtecan) 2L in gastric
    C. Robert, H. Rugo, C. Saura, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  183. Abstract 94472026-04-01 · 16:00 CT · S406
    Long-term follow-up of Keytruda neoadjuvant for NSCLC: KEYNOTE-613
    S. Peters, S. Modi · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  184. Abstract 91782026-04-03 · 19:00 CT · Arie Crown Theater
    DESTINY-Breast-802: Enhertu (trastuzumab deruxtecan) 2L in NSCLC
    J. Cortes, H. Rugo, L. Paz-Ares, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  185. Abstract 11482026-04-02 · 16:15 CT · S406
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-634 study)
    J. Brahmer, S. Modi, C. Robert, et al. · Stanford Cancer Institute
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  186. Abstract 41942026-04-04 · 20:30 CT · E450
    Trodelvy plus chemotherapy in previously untreated urothelial carcinoma: updated analysis from ASCENT-934
    M. Krop, J. Brahmer, J. Cortes, et al. · Princess Margaret Cancer Centre
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  187. Abstract 45502026-04-04 · 16:15 CT · Hall B1
    Quality of life outcomes with Imfinzi in patients with biliary tract
    L. Paz-Ares, E. Winer, G. Curigliano, et al. · Mayo Clinic
    Rapid Oral Abstract SessionGastrointestinal Cancer📄🖼️🎬
  188. Abstract 93342026-04-04 · 13:00 CT · S100A
    Quality of life outcomes with Imfinzi in patients with SCLC
    M. Krop, P. Schmid, S. Tolaney, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  189. Abstract 16872026-04-04 · 20:00 CT · Hall B1
    Biomarker subgroup analysis of Ibrance in HR+ breast cancer (the PALOMA-73 study)
    J. Brahmer, S. Peters, C. Robert, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  190. Abstract 19782026-04-03 · 21:15 CT · Arie Crown Theater
    PALOMA-168: Ibrance (palbociclib) neoadjuvant in HR+ breast cancer
    L. Paz-Ares, J. Cortes, P. Schmid, et al. · MD Anderson Cancer Center
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  191. Abstract 97862026-04-03 · 21:15 CT · S406
    Long-term follow-up of Tagrisso neoadjuvant for NSCLC: FLAURA-54
    H. Rugo, P. Schmid, S. Tolaney, et al. · Massachusetts General Hospital
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  192. Abstract 14952026-04-03 · 16:15 CT · S100A
    OlympiA-553: Lynparza (olaparib) maintenance in HR+ breast cancer
    T. Mok, N. Rizvi · Peter MacCallum Cancer Centre
    Rapid Oral Abstract SessionBreast Cancer—Metastatic📄🖼️🎬
  193. Abstract 92562026-04-05 · 16:45 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-742
    C. Robert, S. Antonia, P. Schmid, et al. · Institut Gustave Roussy
    Rapid Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  194. Abstract 44562026-04-02 · 15:30 CT · S100A
    EV-565: Padcev (enfortumab vedotin) adjuvant in urothelial carcinoma
    S. Peters, F. Andre, M. Krop, et al. · Memorial Sloan Kettering Cancer Center
    Rapid Oral Abstract SessionGenitourinary Cancer—Kidney/Bladder📄🖼️🎬
  195. Abstract 95622026-04-03 · 19:45 CT · S100A
    CheckMate-570: Opdivo (nivolumab) 2L in metastatic melanoma
    S. Tolaney, S. Antonia · Royal Marsden Hospital
    Rapid Oral Abstract SessionMelanoma📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.